Bayer taps Iambic’s AI platform in new drug discovery collaboration

German pharma major Bayer (BAYN: DE) has entered an artificial intelligence (AI)-driven drug discovery collaboration with US biotech Iambic Therapeutics, as large drugmakers continue to test whether AI platforms can improve early-stage research productivity.

The companies said the collaboration will focus on small-molecule discovery, with Bayer using Iambic’s AI-driven platform, including its Enchant and NeuralPLexer technologies, to identify novel drug entry points and differentiated molecules against hard-to-drug targets.